<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A Cochrane analysis concluded that glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) analogues were effective for the improvement of glycaemic control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="?"><plain>What is the significance for the treatment of Danish patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In Denmark, two drugs exist, exenatid and liraglutid, and they both reduce HbA1c with approx </plain></SENT>
<SENT sid="3" pm="."><plain>1% </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> and insulin, the advantage of GLP-1 analogues is not only that they rarely induce <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, but also that body weight is reduced </plain></SENT>
<SENT sid="5" pm="."><plain>On the other hand, no long-term results exist with regard to impact on the cardiovascular system, and no complete overview of possible side effects has been presented either </plain></SENT>
</text></document>